Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark

Figures & data

Table I. Diagnosis (A) and clinical characteristics (B) at time of referral to TSEBT.

(A) Diagnosis	High-dose	Low-dose	Percentage
Mycosis fungoides	17	10	77.1%
Mycosis fungoides variants and subtypes	3	0	8.6%
Folliculotropic mycosis fungoides	1	0	2.9%
Sézary syndrome	1	0	2.9%
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional)	1	0	2.9%
Cutaneous g/d T-cell lymphoma (provisional)	1	0	2.9%
Primary cutaneous CD4+ small/medium size pleomorpic T-cell lymphoma (provisional)	1	0	2.9%
Total	25	10	100%
(B) Stage at time of referral	High-dose	Low-dose	Percentage
CTCL	25	10	100%
T1 (patch/plaque < 10% BSA)	0	2	5.7%
T2 (patch/plaque > 10% BSA)	9	5	40.0%
T3 (Tumor)	14	3	48.6%
T4 (Erythroderma)	2	0	5.7%

BSA, body skin area.

Figure 1. Freedom-from-progression (FFP) was significantly increased in patients treated with high-dose (solid line) (n = 25) compared to low-dose (stabled line) (n = 10) TSEBT treated patients, p < 0.01.

Table II. Overall response to high-dose TSEBT.

Stage (high-dose)	Number	CR	PR	NR	CR + PR
T1 (patch/plaque < 10% BSA)	0	0	0	0	0
T2 (patch/plaque > 10% BSA)	9	6 (66.7%)	3 (33.3%)	0	9 (100%)
T3 (Tumor)	14	11 (78.6%)	3 (21.4%)	0	14 (100%)
T4 (Erythroderma)	2	0	2 (100%)	0	2 (100%)
Total	25	17 (68.0%)	8 (32.0%	0	25 (100%)

BSA, body skin area; CR, complete response; PR, partial response; NR, no response.

Figure 2. Freedom-from-relapse (FFR) outcome of patients treated with high-dose TSEBT with T2 (solid line) and T3 (stabled line) disease, who achieved CR (p = 0.77).